Millionaire Investor Reveals: “How I Made My Second Fortune… By Avoiding 99% of Stocks”
Buy this small group of unique stocks… never sell them… and make all the money you need… No matter what happens in the market.

Revealed here: the name and ticker of the #1 stock.
>>>
pixel
Azita Saleki-Gerhardt net worth and biography

Azita Saleki-Gerhardt Biography and Net Worth

EVP of AbbVie
Dr. Azita Saleki-Gerhardt is Executive Vice President, Operations, leading a global team of scientific, manufacturing, engineering, quality, and supply chain professionals responsible for supply and distribution of all AbbVie products, as well as several enterprise services, including facilities, purchasing and security.

Dr. Saleki-Gerhardt joined Abbott in 1993 as a research scientist. She has worked in key leadership positions of increasing responsibility across a broad range of areas, including science and technology and quality assurance. In 2011, she assumed the role of President, Global Pharmaceutical Operations at Abbott.  Following AbbVie’s separation from Abbott in 2013, Dr. Saleki-Gerhardt was appointed to lead Operations at AbbVie.  She also serves as the chair of AbbVie’s executive crisis management team, where she is responsible for the company’s cross-functional preparedness and response to ongoing issues.

She has been published in a number of scientific publications and has been awarded several patents related to pharmaceutical sciences.

Dr. Saleki-Gerhardt is a member of the board of directors for Entegris. She is a member of the Dean’s Advisory Boards for the School of International Studies and School of Pharmacy at the University of Wisconsin at Madison. At AbbVie, she is the executive chair of the Women Leaders in Action employee resource group. She is a recent alumna of the board of directors for United Way of Lake County.

Dr. Saleki-Gerhardt earned her bachelor’s, master’s, and doctorate degrees in pharmaceutics from the University of Wisconsin at Madison.

What is Azita Saleki-Gerhardt's net worth?

The estimated net worth of Azita Saleki-Gerhardt is at least $15.27 million as of March 5th, 2019. Dr. Saleki-Gerhardt owns 93,312 shares of AbbVie stock worth more than $15,271,442 as of December 3rd. This net worth estimate does not reflect any other investments that Dr. Saleki-Gerhardt may own. Learn More about Azita Saleki-Gerhardt's net worth.

How old is Azita Saleki-Gerhardt?

Dr. Saleki-Gerhardt is currently 59 years old. There are 6 older executives and no younger executives at AbbVie. The oldest executive at AbbVie is Mr. Richard A. Gonzalez, Chairman & CEO, who is 68 years old. Learn More on Azita Saleki-Gerhardt's age.

How do I contact Azita Saleki-Gerhardt?

The corporate mailing address for Dr. Saleki-Gerhardt and other AbbVie executives is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. AbbVie can also be reached via phone at (847) 932-7900. Learn More on Azita Saleki-Gerhardt's contact information.

Has Azita Saleki-Gerhardt been buying or selling shares of AbbVie?

Azita Saleki-Gerhardt has not been actively trading shares of AbbVie during the last ninety days. Most recently, Azita Saleki-Gerhardt sold 15,797 shares of the business's stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $79.03, for a transaction totalling $1,248,436.91. Following the completion of the sale, the executive vice president now directly owns 93,312 shares of the company's stock, valued at $7,374,447.36. Learn More on Azita Saleki-Gerhardt's trading history.

Who are AbbVie's active insiders?

AbbVie's insider roster includes Carlos Alban (Vice Chairman), Roxanne Austin (Director), Nicholas Donoghoe (SVP), Brian Durkin (VP), Richard Gonzalez (CEO), Henry Gosebruch (EVP), Robert Michael (Vice Chairman), Scott Reents (Sr. VP & CFO ), Timothy Richmond (EVP), Azita Saleki-Gerhardt (EVP), Laura Schumacher (Vice Chairman), Michael Severino (Vice Chairman), Elaine Sorg (SVP), Jeffrey Stewart (EVP), and Carrie Strom (SVP). Learn More on AbbVie's active insiders.

Are insiders buying or selling shares of AbbVie?

During the last year, insiders at the sold shares 16 times. They sold a total of 997,100 shares worth more than $140,525,236.75. The most recent insider tranaction occured on May, 23rd when Vice Chairman Michael Severino sold 79,801 shares worth more than $12,041,970.90. Insiders at AbbVie own 0.1 % of the company. Learn More about insider trades at AbbVie.

Information on this page was last updated on 5/23/2022.

Azita Saleki-Gerhardt Insider Trading History at AbbVie

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/5/2019Sell15,797$79.03$1,248,436.9193,312View SEC Filing Icon  
9/11/2017Sell8,300$85.02$705,666.0093,099View SEC Filing Icon  
3/3/2014Sell2,443$50.25$122,760.7585,828View SEC Filing Icon  
9/17/2013Sell10,473$45.84$480,082.3266,703View SEC Filing Icon  
8/19/2013Sell1,270$43.01$54,622.7064,279View SEC Filing Icon  
8/12/2013Sell8,851$44.91$397,498.4164,237View SEC Filing Icon  
See Full Table

Azita Saleki-Gerhardt Buying and Selling Activity at AbbVie

This chart shows Azita Saleki-Gerhardt's buying and selling at AbbVie by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AbbVie Company Overview

AbbVie logo
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read More

Today's Range

Now: $163.66
Low: $160.51
High: $163.76

50 Day Range

MA: $148.46
Low: $134.21
High: $163.66

2 Week Range

Now: $163.66
Low: $117.00
High: $175.91

Volume

4,252,299 shs

Average Volume

6,597,847 shs

Market Capitalization

$289.43 billion

P/E Ratio

21.85

Dividend Yield

3.49%

Beta

0.7
Millionaire Investor Reveals: “How I Made My Second Fortune… By Avoiding 99% of Stocks”
Buy this small group of unique stocks… never sell them… and make all the money you need… No matter what happens in the market.

Revealed here: the name and ticker of the #1 stock.
>>>
pixel